Delta-Fly Pharma Inc. 



801-1080 Howe Street

Vancouver, BC V6Z 2T1 Canada

Member Sector:  Biopharmaceuticals

Delta-Fly Pharma is a Japanese biopharmaceutical company that aims to make cancer drug development faster, cheaper and more efficient.  

Delta-Fly employs an assembly approach to drug development through the concept of module technology. Rather than begin with targets, Delta-Fly starts with existing drugs that have suboptimal risk-benefit profiles. Using its experience with polymers and broad R&D expertise, Delta-Fly enhances the safety and efficacy of these compounds and quickly modifies them to create new drug variations.

With this module technology, Delta-Fly has bypassed elements of early-stage research to quickly build a broad pipeline of oncology drugs led by a Phase 3 leukemia candidate in development in the US.

Established in 2010 and listed on the Tokyo Stock Exchange in 2018, Delta-Fly is advancing its global business with the opening of a North American office in Vancouver, BC.